Nirman Agri Genetics (NIRMAN) Stock Overview
Operates as an agri-input company in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
NIRMAN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Nirman Agri Genetics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹161.40 |
| 52 Week High | ₹456.00 |
| 52 Week Low | ₹130.10 |
| Beta | 0.43 |
| 1 Month Change | 18.55% |
| 3 Month Change | -14.90% |
| 1 Year Change | -52.27% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 59.33% |
Recent News & Updates
Recent updates
Positive Sentiment Still Eludes Nirman Agri Genetics Limited (NSE:NIRMAN) Following 26% Share Price Slump
Jul 19
Positive Sentiment Still Eludes Nirman Agri Genetics Limited (NSE:NIRMAN) Following 26% Share Price Slump
Jul 19Investors Give Nirman Agri Genetics Limited (NSE:NIRMAN) Shares A 27% Hiding
Mar 29Calculating The Intrinsic Value Of Nirman Agri Genetics Limited (NSE:NIRMAN)
Mar 19Nirman Agri Genetics Limited (NSE:NIRMAN) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Feb 12Should You Be Adding Nirman Agri Genetics (NSE:NIRMAN) To Your Watchlist Today?
Jan 08Here's Why We Think Nirman Agri Genetics (NSE:NIRMAN) Might Deserve Your Attention Today
Aug 13Nirman Agri Genetics Limited (NSE:NIRMAN) Stock Rockets 47% But Many Are Still Ignoring The Company
Jul 03Shareholder Returns
| NIRMAN | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | -18.5% | 3.5% | 1.5% |
| 1Y | -52.3% | 1.4% | -4.7% |
Return vs Industry: NIRMAN underperformed the Indian Biotechs industry which returned 1.4% over the past year.
Return vs Market: NIRMAN underperformed the Indian Market which returned -4.7% over the past year.
Price Volatility
| NIRMAN volatility | |
|---|---|
| NIRMAN Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 4.7% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: NIRMAN's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: NIRMAN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Pranav Bagal | www.nirmanagrigen.com |
Nirman Agri Genetics Limited operates as an agri-input company in India. The company produces, processes, and markets hybrid seeds, pesticides, and bio-organics for various corps, including corn, tomato, okra, capsicum, gourds, and bajra, as well as sunflower, cotton, paddy, and grain sorghum. It also offers non-hybrid seeds for paddy.
Nirman Agri Genetics Limited Fundamentals Summary
| NIRMAN fundamental statistics | |
|---|---|
| Market cap | ₹962.07m |
| Earnings (TTM) | ₹252.86m |
| Revenue (TTM) | ₹2.37b |
Is NIRMAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NIRMAN income statement (TTM) | |
|---|---|
| Revenue | ₹2.37b |
| Cost of Revenue | ₹2.05b |
| Gross Profit | ₹315.35m |
| Other Expenses | ₹62.49m |
| Earnings | ₹252.86m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 42.42 |
| Gross Margin | 13.32% |
| Net Profit Margin | 10.68% |
| Debt/Equity Ratio | 0.4% |
How did NIRMAN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 07:28 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nirman Agri Genetics Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.